Modulating Expression of the Metastasis Suppressor MxA
Description of Invention:
The invention discloses compounds that could be used to inhibit metastases. The compounds of the current invention were discovered by high-throughput screening of a novel cell line engineered with a MxA reporter. The compounds could be used to treat metastatic cancers including prostate and melanomas by increasing MxA expression.
MxA expression reduces cell motility and metastases in a mouse model. Cells expressing MxA produced smaller tumors in engrafted mice compared to controls. When injected into mouse spleens, cells expressing MxA showed a significantly delayed metastasis, and the mice survived significantly longer than controls. Expression of MxA reduced cellular motility of prostate cancer cell lines in vitro and reduced cellular motility and invasiveness of the highly metastatic melanoma cell line LOX.
Patent Status:
DHHS Reference No. E-257-2004/0 --
U.S. Provisional Application No. 60/613,371 filed 27 Sep 2004
PCT Application No. PCT/US2005/034849 filed 27 Sep 2005, which published as WO 2006/037052 on 06 Apr 2006
U.S. Patent Application filed 27 Mar 2007
Portfolios: Cancer
Cancer -Diagnostics Cancer -Therapeutics
For Additional Information Please Contact: Whitney Hastings
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: 301/451-7337
Email: hastingw@mail.nih.gov
Fax: 301/402-0220
